Expert Financial Analysis and Reporting

Recent Reports

• Cytokinetics: Current Investment Thesis Is All About Omecamtiv Mecarbil (CYTK. $13.26, Buy) (0)

Recent Blogs

• Cryoport; Sales of CAR-T Products Yescarta and Kymriah are In-line with My Projections (CYRX, Buy, $20.67) (0)
• Cryoport: Quick Take on 2Q Results (CYRX, $20.18, Buy) (0)
• Part 10 of Illegal Naked Shorting Series:  Legal Shorting of Stocks is a Loser’s Game but Illegal Naked Shorting Transforms It into a Winner’s Game (0)
• Portola: Andexxa Looks to be a Blockbuster (PTLA, $30.00, Buy) (0)
• Part 9 of Illegal Naked Shorting Series:  The Risk/ Reward of Shorting Versus Buying Stocks is Extremely Unfavorable (0)
• Antares: Highlights from 2Q, 2019 Conference Call (ATRS, $3.29, Buy) (0)
• Part 8: Illegal Naked Shorting Series: Who or What is Cede and What Role Does Cede Play in the Trading of Stocks? (0)
• New Approach to SmithOnStocks Reports Starts with Aimmune Therapeutics (AIMT, $18.73) (0)
• Part 7: Illegal Naked Shorting: DTCC Continuous Net Settlement and Stock Borrowing Programs Have Loopholes That Facilitate Illegal Naked Shorting (0)
• Antares Pharma: The Xyosted Launch Continues to Look Good (ATRS, Buy, $3.37) (0)
• Part 6 Illegal Naked Shorting: The SEC’s Regulation SHO is Intended to Prevent Illegal Naked Shorting, But is Ineffective (0)

Social Feeds

• • $ CYRX Cryoport: The Bristol-Myers Acquisition of Celgene is a Validation of my Investment Thesis for Cryoport… https://t.co/TQ4KFbritg, Jan 09
  • $PTLA Portola: Tidbits from Presentation at JP Morgan Healthcare Conference (PTLA, Buy, $21.96) https://t.co/76AuWyEbFH, Jan 09
  • $BMY Negative Market Reaction to Celgene Acquisition is a Buying Opportunity https://t.co/0aybnueJbx, Jan 04
  • $nwbo $46 million non-dilutive financing provides major boost to investment outlook. See my report. https://t.co/pidvWRoYUR, Dec 17
  • $cyrx Cryoport raises a $25 million warchest for acquisiitons https://t.co/OyAt5ZlY87, Dec 17